AstraZeneca and Bristol Myers Squibb in $400 Billion Merger Talks

AstraZeneca AZN and Bristol Myers Squibb BMY held preliminary talks about a possible combination that would create a company with a combined value near $400 billion, the Financial Times first reported on August 2, 2026. The figure describes the scale of the potential merged entity rather than a disclosed deal price, and both companies have declined to comment on the report.

The market reacted sharply and asymmetrically: AstraZeneca shares fell as much as 7% while Bristol Myers Squibb rose about 6% in U.S. premarket trading, a split that reflects how investors are pricing the deal as a rescue of BMY's weaker pipeline rather than a merger of equals. Analysts described themselves as "perplexed" by AstraZeneca's apparent interest, questioning why a stronger, faster-growing company would dilute its position by combining with a smaller peer .

A central risk investors are weighing is antitrust exposure. Oncology accounted for more than 40% of Bristol Myers Squibb's first-half 2026 sales, and the two companies' cancer immunotherapy franchises compete directly in several tumor types, an overlap that could draw sustained scrutiny from U.S. and European regulators and force divestitures before any deal could close. This would not be AstraZeneca's first brush with a transformative merger: the company rejected a hostile approach from Pfizer in 2014, when then-and-current CEO Pascal Soriot argued AstraZeneca could generate more value as an independent company than Pfizer's roughly $118 billion offer implied.

For now the talks remain preliminary and unconfirmed by either party. Investors should watch for a formal statement from AstraZeneca or Bristol Myers Squibb, any regulatory signaling from the FTC or European Commission, and whether analyst commentary shifts from skepticism toward assigning real deal probability.

Related Stocks

• AZN
• BMY
• PFE